L3VLUP
ProSign in

BSX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BSXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BSX
  • VRTX
0204060202120222023202420252026
Holders and value by quarter
QuarterBSXVRTX
Q3 202031 holders, $15.0bn31 holders, $21.9bn
Q4 202035 holders, $13.6bn30 holders, $18.4bn
Q1 202129 holders, $15.7bn31 holders, $15.4bn
Q2 202127 holders, $18.2bn30 holders, $12.7bn
Q3 202127 holders, $18.2bn35 holders, $10.1bn
Q4 202126 holders, $17.4bn28 holders, $12.4bn
Q1 202232 holders, $17.4bn23 holders, $16.1bn
Q2 202230 holders, $14.0bn25 holders, $18.1bn
Q3 202229 holders, $14.5bn22 holders, $18.4bn
Q4 202226 holders, $16.6bn28 holders, $18.4bn
Q1 202332 holders, $18.5bn26 holders, $21.4bn
Q2 202337 holders, $19.6bn27 holders, $24.7bn
Q3 202333 holders, $19.7bn33 holders, $24.3bn
Q4 202330 holders, $20.6bn32 holders, $28.6bn
Q1 202433 holders, $24.0bn31 holders, $29.8bn
Q2 202435 holders, $26.8bn29 holders, $33.4bn
Q3 202440 holders, $28.3bn27 holders, $33.5bn
Q4 202440 holders, $29.4bn26 holders, $28.5bn
Q1 202544 holders, $33.1bn21 holders, $35.4bn
Q2 202544 holders, $33.6bn21 holders, $32.3bn
Q3 202548 holders, $29.5bn22 holders, $25.9bn
Q4 202549 holders, $28.5bn26 holders, $31.8bn
Q1 202645 holders, $17.2bn25 holders, $31.8bn
Q2 202640 holders, $13.0bn26 holders, $34.6bn
BSX

Boston Scientific Corp

Holders
44
Reported value
$33.6bn
Buyers
24
Sellers
21

Breadth +3 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 47 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BSX (26)

Acadian Asset Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, ExodusPoint Capital Management LP, Farallon Capital Management LLC, GAMCO Investors Inc, Holocene Advisors LP, Millennium Management LLC, PDT Partners LLC, Point72 Asset Management LP, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC, Steadfast Capital Management LP, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Viking Global Investors LP, Voloridge Investment Management LLC, and 1 more

Only VRTX (3)

ARK Investment Management LLC, Baillie Gifford & Co, Squarepoint Ops LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →